IJR News — today's news from every sideTom Gallagher Employers in tech will face more turnover costs and delays when trying to fill specialized roles. Dr. David Crean Book Guides Biopharma Leaders on Commercialization — Sep 18, 2026A new book, Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences by Dr. David H. Crean, offers a practical blueprint for biopharma to move from discovery to commercialization by focusing on three core translations—Data to Capital, Discovery to Deal, and Bench to Boardroom—along with Capital Stack Optimization. Aimed at scientist-founders, pre-commercial CEOs, BD executives, and investors, the work promises actionable risk-reduction insights and will be available on Amazon and major bookstores through Cardiff Advisory LLC.
Jared Kim This book seems helpful for scientist founders who struggle turning research into actual funding and governance plans.Perseverance Asset Management International Expands Holdings in NetEase, FUTU, PDD, MOS, HTHT in Q1 — Jul 24, 2026Perseverance Asset Management International expanded its stakes in several companies in Q1, including adding 60,000 NetEase shares to reach 170,000; purchasing 150,000 Futu shares; and buying 300,000 Mosaic shares, while PDD Holdings became the fund’s largest position with about 2.16 million shares. The firm also reduced its H World Group stake by roughly 25% and saw continued activity from other funds across these positions.
